• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

注射部位和调节性T细胞影响持久的疫苗诱导的针对过度表达的自身肿瘤相关抗原的肿瘤免疫。

Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.

作者信息

Bright Jennifer D, Schultz Heather N, Byrne Jennifer A, Bright Robert K

机构信息

Department of Immunology and Molecular Microbiology; Texas Tech University Health Sciences Center; Lubbock, TX USA.

出版信息

Oncoimmunology. 2013 Jul 1;2(7):e25049. doi: 10.4161/onci.25049. Epub 2013 May 21.

DOI:10.4161/onci.25049
PMID:24073379
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3782160/
Abstract

Tumor protein D52 (D52) is constitutively expressed in healthy tissues and overexpressed in multiple cancers, including (but not limited to) breast, prostate and ovarian carcinomas. Although the normal functions of D52 are unknown, it is clear that increased D52 expression levels not only stimulate cell proliferation and metastasis, but also correlate with poor prognosis in a subset of breast cancer patients. The murine orthologs of D52 (mD52) shares 86% identity with its human counterpart (hD52) and mirrors hD52 expression patterns. The forced overexpression of mD52 induces anchorage-independent growth in vitro and promotes tumor formation as well as spontaneous metastasis in vivo. We have previously reported that the intramuscular administration of recombinant mD52 elicits immune responses capable of rejecting a challenge with tumor cells and preventing spontaneous metastasis only in 50% of mice. We hypothesized that mechanisms of peripheral tolerance dampen immune responses against mD52, thus limiting the protective effects of vaccination. To test this hypothesis, mice were depleted of CD25 regulatory T cells (Tregs) and subcutaneously immunized with mD52 prior to a tumor challenge. The subcutaneous immunization failed to induce protective antitumor immunity unless accompanied by Treg depletion, which resulted in a rate of protection of 70% as compared with.

摘要

肿瘤蛋白D52(D52)在健康组织中组成性表达,在多种癌症中过表达,包括(但不限于)乳腺癌、前列腺癌和卵巢癌。尽管D52的正常功能尚不清楚,但很明显,D52表达水平的升高不仅刺激细胞增殖和转移,而且与一部分乳腺癌患者的预后不良相关。D52的小鼠直系同源物(mD52)与其人类对应物(hD52)具有86%的同一性,并反映hD52的表达模式。mD52的强制过表达在体外诱导不依赖贴壁生长,并促进体内肿瘤形成以及自发转移。我们之前报道,肌肉注射重组mD52仅在50%的小鼠中引发能够排斥肿瘤细胞攻击并预防自发转移的免疫反应。我们假设外周耐受机制会抑制针对mD52的免疫反应,从而限制疫苗接种的保护作用。为了验证这一假设,在肿瘤攻击前,对小鼠进行CD25调节性T细胞(Tregs)清除,并皮下免疫mD52。皮下免疫未能诱导保护性抗肿瘤免疫,除非伴有Treg清除,与……相比,Treg清除后的保护率为70%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/e79792396265/onci-2-e25049-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/0adf335d5415/onci-2-e25049-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/6a3b030d2d90/onci-2-e25049-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/11f0dd54e2a7/onci-2-e25049-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/7889f0e2c782/onci-2-e25049-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/5caeb31687f0/onci-2-e25049-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/e79792396265/onci-2-e25049-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/0adf335d5415/onci-2-e25049-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/6a3b030d2d90/onci-2-e25049-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/11f0dd54e2a7/onci-2-e25049-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/7889f0e2c782/onci-2-e25049-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/5caeb31687f0/onci-2-e25049-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/3782160/e79792396265/onci-2-e25049-g6.jpg

相似文献

1
Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.注射部位和调节性T细胞影响持久的疫苗诱导的针对过度表达的自身肿瘤相关抗原的肿瘤免疫。
Oncoimmunology. 2013 Jul 1;2(7):e25049. doi: 10.4161/onci.25049. Epub 2013 May 21.
2
Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.接种与转移相关的肿瘤相关抗原TPD52和CpG/ODN可诱导保护性肿瘤免疫。
Cancer Immunol Immunother. 2008 Jun;57(6):799-811. doi: 10.1007/s00262-007-0416-y. Epub 2007 Oct 26.
3
Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.用可溶性粒细胞-巨噬细胞集落刺激因子(GM-CSF)给予编码自身抗原TPD52的DNA疫苗所诱导的记忆和细胞免疫。
Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.
4
Preclinical support for tumor protein D52 as a cancer vaccine antigen.肿瘤蛋白 D52 作为癌症疫苗抗原的临床前支持。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2273699. doi: 10.1080/21645515.2023.2273699. Epub 2023 Oct 30.
5
Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.肿瘤蛋白D52的小鼠同源物诱导肿瘤发生和转移
Mol Cancer Res. 2007 Feb;5(2):133-44. doi: 10.1158/1541-7786.MCR-06-0245.
6
Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype.接种具有共同致癌肿瘤自身抗原的疫苗会引发一群具有调节表型的 CD8+ T 细胞。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2108656. doi: 10.1080/21645515.2022.2108656. Epub 2022 Sep 7.
7
Overexpressed oncogenic tumor-self antigens.过度表达的致癌肿瘤自身抗原。
Hum Vaccin Immunother. 2014;10(11):3297-305. doi: 10.4161/hv.29475.
8
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.对致癌性肿瘤自身蛋白D52疫苗接种引发的CD8+ IL-10+ T细胞反应的分析。
Hum Vaccin Immunother. 2020 Jun 2;16(6):1413-1423. doi: 10.1080/21645515.2019.1689746. Epub 2019 Nov 26.
9
Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52).
Genomics. 1996 Aug 1;35(3):523-32. doi: 10.1006/geno.1996.0393.
10
Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.肿瘤蛋白D52样蛋白的非冗余功能支持对TPD52的特异性靶向。
Clin Cancer Res. 2008 Aug 15;14(16):5050-60. doi: 10.1158/1078-0432.CCR-07-4994.

引用本文的文献

1
Preclinical support for tumor protein D52 as a cancer vaccine antigen.肿瘤蛋白 D52 作为癌症疫苗抗原的临床前支持。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2273699. doi: 10.1080/21645515.2023.2273699. Epub 2023 Oct 30.
2
Selective depletion of regulatory T cells enhances the immunogenicity of a recombinant-based vaccine against spp.特异性耗竭调节性 T 细胞增强重组疫苗对 spp.的免疫原性
Front Cell Infect Microbiol. 2023 Feb 10;12:1084526. doi: 10.3389/fcimb.2022.1084526. eCollection 2022.
3
Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype.

本文引用的文献

1
Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.在人类癌症中识别候选扩增靶点的挑战:以8号染色体q21为例进行研究
Genes Cancer. 2012 Feb;3(2):87-101. doi: 10.1177/1947601912456287.
2
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.肿瘤免疫原性和对癌症疫苗治疗的反应性:最新进展。
Semin Immunol. 2010 Jun;22(3):105-12. doi: 10.1016/j.smim.2010.02.001. Epub 2010 Mar 11.
3
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
接种具有共同致癌肿瘤自身抗原的疫苗会引发一群具有调节表型的 CD8+ T 细胞。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2108656. doi: 10.1080/21645515.2022.2108656. Epub 2022 Sep 7.
4
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.对致癌性肿瘤自身蛋白D52疫苗接种引发的CD8+ IL-10+ T细胞反应的分析。
Hum Vaccin Immunother. 2020 Jun 2;16(6):1413-1423. doi: 10.1080/21645515.2019.1689746. Epub 2019 Nov 26.
5
Dendritic cell-based vaccine efficacy: aiming for hot spots.基于树突状细胞的疫苗疗效:瞄准热点。
Front Immunol. 2015 Mar 3;6:91. doi: 10.3389/fimmu.2015.00091. eCollection 2015.
6
Overexpressed oncogenic tumor-self antigens.过度表达的致癌肿瘤自身抗原。
Hum Vaccin Immunother. 2014;10(11):3297-305. doi: 10.4161/hv.29475.
7
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?肿瘤蛋白D52(TPD52)以及癌症原癌基因——是研究不足的基因还是未充分研究的原癌基因?
Tumour Biol. 2014 Aug;35(8):7369-82. doi: 10.1007/s13277-014-2006-x. Epub 2014 May 6.
CD122+CD8+ Treg 抑制淋巴耗竭小鼠的疫苗诱导抗肿瘤免疫反应。
Eur J Immunol. 2010 May;40(5):1375-85. doi: 10.1002/eji.200839210.
4
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.癌症抗原的优先级排序:美国国立癌症研究所加速转化研究的试点项目
Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.
5
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.编码TPD52的重叠合成肽作为小鼠乳腺癌疫苗:延长生存期。
Vaccine. 2009 Mar 13;27(12):1825-33. doi: 10.1016/j.vaccine.2009.01.089. Epub 2009 Feb 6.
6
Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.用可溶性粒细胞-巨噬细胞集落刺激因子(GM-CSF)给予编码自身抗原TPD52的DNA疫苗所诱导的记忆和细胞免疫。
Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.
7
Generation and regulation of CD8(+) regulatory T cells.CD8(+)调节性T细胞的产生与调控。
Cell Mol Immunol. 2008 Dec;5(6):401-6. doi: 10.1038/cmi.2008.50.
8
Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays.基于多种微阵列分析的肿瘤中肿瘤蛋白D52的过表达与基因扩增
Crit Rev Oncog. 2008;14(1):33-55. doi: 10.1615/critrevoncog.v14.i1.30.
9
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.在T细胞介导的癌胚抗原靶向治疗中平衡抗肿瘤疗效与自身免疫病理反应。
Cancer Res. 2008 Oct 15;68(20):8446-55. doi: 10.1158/0008-5472.CAN-08-1864.
10
Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination.传染病与疫苗接种中的人类CD4和CD8调节性T细胞
Hum Immunol. 2008 Nov;69(11):760-70. doi: 10.1016/j.humimm.2008.07.017. Epub 2008 Oct 7.